Columbia University

Technology Ventures

Belite Bio

Belite Bio: Belite Bio is a clinical stage company focused on First-in-Class therapeutics targeting untreatable diseases, including Dry Age-related Macular Degeneration (Dry AMD), Stargardt disease (juvenile macular degeneration), and NASH (Nonalcoholic steatohepatitis). The Retinol Binding Protein 4 (“RBP4”) platform library was developed by Columbia's Dr. Konstantin Petrukhin, and Belite Bio holds the global exclusive license from Columbia. This platform covers around 500 structurally distinct RBP4 antagonists under patent protection. The lead candidate LBS-008 is currently in a phase 1 clinical trial. RBP4 is a carrier protein that transports vitamin A (retinol) to peripheral tissues, especially to the eyes. Excess amounts of vitamin A in the retina with associated accumulation of toxic byproducts is the key pathogenesis of Dry AMD and Stargardt disease. LBS-008 works by modulating excess retinol in circulation to lower its concentration in the retina. LBS-008 has been awarded Orphan Drug Designation in the US and Europe, and Rare Pediatric Disease Designation in the US, for Stargardt disease.

To learn more about this opportunity, contact: 

Ron Katz
Associate Director of Manhattanville Licensing
ron.katz@columbia.edu